# Targeted stakeholder consultation on the pilot project 'Market Launch Intentions of Centrally Authorised Products'

Fields marked with \* are mandatory.

#### Introduction

#### Objective of the consultation

In the EU, a medicinal product can be placed on the market after it has received a marketing authorisation. A centralized marketing authorisation granted by the European Commission is valid throughout the EU, allowing the marketing of the medicinal product in all Member States. However, in practice, there are still important differences as regards when (if at all) a newly (centrally) authorised medicine is made available in each EU Member State.

The lack of availability of medicinal products in many Member States, particularly in those with smaller population sizes, is a general concern that has also been highlighted in the roadmap of the recently published Pharmaceutical Strategy for Europe. It poses a particular challenge to the underlying principle of the centralised authorisation procedure. This procedure was designed to serve wide availability to patients and healthcare professionals throughout the EU by allowing marketing authorisation holders to commercialise authorised medicinal products in each Member State based on a single marketing authorisation.

In order to increase availability of CAPs, an ad hoc working group was set-up under the Human Pharmaceutical Committee, bringing together the Commission, national competent authorities and the European Medicines Agency, to consider possible actions which could help improve a wider roll-out of CAPs. One of the agreed actions is a 'pilot project' to raise awareness on this issue and engage with prospective marketing authorisation holders through voluntary sharing of their marketing intentions for specific types of CAPs in the preauthorisation phase, and to improve regulators' knowledge on the mechanism behind delayed market launch. . Prospective marketing authorisation holders participating in this pilot will be invited share information confidential to this on а basis.

This pilot will be restricted to MAHs of orphan medicines and/or oncology medicines.

With this online consultation, we seek the stakeholders' feedback on the proposed pilot project and its template for 'Market Launch Intentions.'

The comments and suggestions received will be considered in the work leading to the implementation of this pilot project, which should start later this year.

Thank you in advance for your time and feedback.

## About you

Bulgarian

\*Language of my contribution

Academic/research institution

Business association

Croatian	
Czech	
Danish	
Dutch	
English	
Estonian	
Finnish	
French	
Gaelic	
German	
Greek	
Hungarian	
Italian	
Latvian	
Lithuanian	
Maltese	
Polish	
Portuguese	
Romanian	
Slovak	
Slovenian	
Spanish	
Swedish	
*I am giving my contribution as	

Company/business organisation
Consumer organisation
EU citizen
Environmental organisation
Non-EU citizen
Non-governmental organisation (NGO)
Public authority
Trade union
Other
* First name
Text of 1 to 150 characters will be accepted
*Surname
Text of 1 to 150 characters will be accepted
*Email (this won't be published)
Text of 1 to 150 characters will be accepted
*Organisation name
Text of 1 to 255 characters will be accepted
*Organisation size
Micro (1 to 9 employees)
Small (10 to 49 employees)
Medium (50 to 249 employees)
Large (250 or more)

## Transparency register number

Text of 1 to 255 characters will be accepted

Check if your organisation is on the <u>transparency register</u>. It's a voluntary database for organisations seeking to influence EU decision-making.

# \*Country of origin

Please add your country of origi	n or that of your organisation		
Afghanistan	Djibouti	Libya	Saint Martin
Åland Islands	Dominica	Liechtenstein	Saint Pierre
			and Miquelon
Albania	Dominican	Lithuania	Saint Vincent
	Republic		and the
			Grenadines
Algeria	Ecuador	Luxembourg	Samoa
American	Egypt	Macau	San Marino
Samoa	El Salvador	O Madagaaaa	Cão Tomá ond
Andorra	El Salvadol	Madagascar	São Tomé and Príncipe
Angola	Equatorial	Malawi	Saudi Arabia
7 tilgold	Guinea	Walawi	Cadai / Ilabia
Anguilla	Eritrea	Malaysia	Senegal
Antarctica	Estonia	Maldives	Serbia
Antigua and	Eswatini	Mali	Seychelles
Barbuda			
Argentina	Ethiopia	Malta	Sierra Leone
Armenia	Falkland Islands	Marshall	Singapore
		Islands	
Aruba	Faroe Islands	Martinique	Sint Maarten
Australia	Fiji	Mauritania	Slovakia
Austria	Finland	Mauritius	Slovenia
Azerbaijan	France	Mayotte	Solomon
			Islands
Bahamas	French Guiana	Mexico	Somalia
Bahrain	French	Micronesia	South Africa
	Polynesia		

4

Bangladesh	French Southern and Antarctic Lands	Moldova	<ul><li>South Georgia and the South Sandwich Islands</li></ul>
Barbados	Gabon	Monaco	South Korea
Belarus	Georgia	Mongolia	South Sudan
Belgium	Germany	Montenegro	Spain
Belize	Ghana	Montserrat	Sri Lanka
Benin	Gibraltar	Morocco	Sudan
Bermuda	Greece	Mozambique	Suriname
Bhutan	Greenland	Myanmar	Svalbard and
		/Burma	Jan Mayen
Bolivia	Grenada	Namibia	Sweden
Bonaire Saint	Guadeloupe	Nauru	Switzerland
Eustatius and			
Saba			
Bosnia and	Guam	Nepal	Syria
Herzegovina			
Botswana	Guatemala	Netherlands	Taiwan
Bouvet Island	Guernsey	New Caledonia	Tajikistan
Brazil	Guinea	New Zealand	Tanzania
British Indian	Guinea-Bissau	Nicaragua	Thailand
Ocean Territory			
British Virgin	Guyana	Niger Niger	The Gambia
Islands			
Brunei	Haiti	Nigeria	Timor-Leste
Bulgaria	Heard Island	Niue Niue	Togo
	and McDonald		
Duding Face	Islands	Naufallu lalau al	O Talvalavi
Burkina Faso	Honduras	Norfolk Island	Tokelau
Burundi	Hong Kong	Northern Mariana Jalanda	Tonga
O Combodia	O Hunger	Mariana Islands	Tripided and
Cambodia	Hungary	North Korea	Trinidad and
			Tobago

Cameroon	Iceland	North Macedonia	Tunisia
Canada	India	Norway	Turkey
Cape Verde	Indonesia	Oman	Turkmenistan
Cayman Islands	Iran	Pakistan	Turks and
•			Caicos Islands
<ul><li>Central African</li><li>Republic</li></ul>	Iraq	Palau	Tuvalu
Chad	Ireland	Palestine	Uganda
Chile	Isle of Man	Panama	Ukraine
China	Israel	Papua New	United Arab
		Guinea	Emirates
Christmas	Italy	Paraguay	United
Island			Kingdom
Clipperton	Jamaica	Peru	United States
Cocos (Keeling)	Japan	Philippines	United States
Islands			Minor Outlying
			Islands
Colombia	Jersey	Pitcairn Islands	Uruguay
Comoros	Jordan	Poland	US Virgin
			Islands
Congo	Kazakhstan	Portugal	Uzbekistan
Cook Islands	Kenya	Puerto Rico	Vanuatu
Costa Rica	Kiribati	Qatar	Vatican City
Côte d'Ivoire	Kosovo	Réunion	Venezuela
Croatia	Kuwait	Romania	Vietnam
Cuba	Kyrgyzstan	Russia	Wallis and
			Futuna
Curação	Laos	Rwanda	Western
			Sahara
Cyprus	Latvia	Saint	Yemen
		Barthélemy	

Czechia	Lebanon	Saint Helena	Zambia
		Ascension and	
		Tristan da	
		Cunha	
Democratic	Lesotho	Saint Kitts and	Zimbabwe
Republic of the		Nevis	
Congo			
Denmark	Liberia	Saint Lucia	

#### \*Publication privacy settings

The Commission will publish the responses to this public consultation. You can choose whether you would like your details to be made public or to remain anonymous.

# Anonymous

Only your type of respondent, country of origin and contribution will be published. All other personal details (name, organisation name and size, transparency register number) will not be published.

Public

Your personal details (name, organisation name and size, transparency register number, country of origin) will be published with your contribution.

I agree with the personal data privacy provisions.

Privacy\_statement.pdf

#### Your input to this consultation


Please read the description of the Pilot Project on 'Market Launch Intentions of Centrally Authorised Products' (the consultation document), which can be downloaded below.

Download the consultation document:

Pilot\_project\_Market\_Launch\_Intentions.pdf

#### Please provide your feedback below.

4000 character(s) maximum



Alternatively, please upload your feedback in Word or PDF format.

#### Please upload your file

The maximum file size is 1 MB
Only files of the type pdf,txt,doc,docx,odt,rtf are allowed

Thank you for your feedback!